Polypharmakos and CABI to develop new antimicrobial products from CABI Culture Collection

  13 May 2021

Polypharmakos Limited, a spin-out company from the UK’s Royal Botanic Gardens Kew and University of Cambridge, and international not-for-profit organisation CABI have signed a research collaboration and licensing agreement to develop novel products from CABI’s Culture Collection.

CABI’s Culture Collection consists of 30,000 strains of optimally preserved fungi and bacteria isolated from diverse ecosystems from around the world – a reflection of CABI’s work and mission to improve lives by solving problems in agriculture and the environment.

Further reading: EurekAlert
Author(s): EurekAlert
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS

BD





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed